ArticleHematology, transfusion and cell therapy
Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature.
Article in Hematology, transfusion and cell therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- A comprehensive analysis of the incidence of chromosomal abnormalities in hematologic malignancies post-COVID-19 outbreak in King Chulalongkorn Memorial Hospital, Thailand.Asian biomedicine : research, reviews and news · 2026Article
- Cytogenetic patterns of hematologic malignancies before, during and after the COVID-19 pandemic: a single-center retrospective study in Thailand.Molecular cytogenetics · 2026Article
- Pulmonary malignant lymphoma requiring surgical lung biopsy for diagnosis following coronavirus disease 2019 infection: a case report.AME case reports · 2026Article
- IL-6 knockdown in a model of the human bone marrow, abrogates DNA damage induction in bystander cells post-chemotherapy induced cytokine release syndrome.Translational oncology · 2024Article
- COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.Cell communication and signaling : CCS · 2024Review
- Productivity losses from short-term work absence due to neoplasms in Poland.Scientific reports · 2024Article
- A familialCold Spring Harbor molecular case studies · 2023Article
- Post-COVID-19 syndrome: Insights into a novel post-infectious systemic disorder.Journal of medicine and life · 2023Review
- Crowdsourcing temporal transcriptomic coronavirus host infection data: Resources, guide, and novel insights.Biology methods & protocols · 2023Article
- Covid-19, leukemia, and secondary malignancies of the skin - is there a connection: a case report and literature analysis.Frontiers in oncology · 2023Article
- SARS-CoV-2 infection as a potential risk factor for the development of cancer.Frontiers in molecular biosciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCoronavirus disease 2019 (COVID-19) may present with extrapulmonary manifestations, including hematologic changes. Previous studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) can interact with the renin-angiotensin system, ultimately causing increased production of angiotensin II. By reporting the cases of previously healthy young adults diagnosed with a hematologic malignancy after experiencing COVID-19, we raise the hypothesis that the SARS-Cov-2 infection could act as a trigger for leukemogenesis in predisposed individuals.
methodsThis was a case series performed through extraction of relevant clinical information from the medical records of three patients admitted to our Hematology unit between August 2020 and September 2020. MAIN
resultsConsidering the relatively rapid development of cytopenias following recovery from COVID-19, it cannot be ruled out that SARS-Cov-2 played a role in leukemogenesis in those patients. Based on previous
conclusionDespite the advances in pathophysiological and clinical characterization of COVID-19, the consequences of the pandemic to the incidence of hematologic diseases are still to be elucidated. In this context, future dissection of the status of the local bone marrow renin-angiotensin system in leukemogenesis is a clinically relevant basic research area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.